Chen Xin, Hui Li, Foster David A, Drain Charles Michael
Department of Chemistry and Biochemistry, Hunter College and the Graduate Center of the City University of New York, 695 Park Avenue, New York, New York 10021, USA.
Biochemistry. 2004 Aug 31;43(34):10918-29. doi: 10.1021/bi049272v.
Since the role of saccharides in cell recognition, metabolism, and cell labeling is well-established, the conjugation of saccharides to drugs is an active area of research. Thus, one goal in the use of saccharide-drug conjugates is to impart a greater specificity toward a given cell type or other targets. Although widely used to treat some cancers and age related macular degeneration, the drugs used in photodynamic therapy (PDT) display poor chemical selectivity toward the intended targets, and uptake by cells most likely arises from passive, diffusional processes. Instead, the specific irradiation of the target tissues, and the formation of the toxic species in situ, are the primary factors that modulate the selectivity in the present mode of PDT. We report herein a two-step method to make nonhydrolyzable saccharide-porphyrin conjugates in high yields using a tetra(pentafluorophenyl)porphyrin and the thio derivative of the sugar. As a demonstration of their properties, the selective uptake (and/or binding) of these compounds to several cancer cell types was examined, followed by an investigation of their photodynamic properties. As expected, different malignant cell types take up one type of saccharide-porphyrin conjugate preferentially over others; for example, human breast cancer cells (MDA-MB-231) absorb a tetraglucose-porphyrin conjugate over the corresponding galactose derivative. Doseametric studies reveal that these saccharide-porphyrin conjugates exhibit varying PDT responses depending on drug concentration and irradiation energy. (1) Using 20 microM conjugate and greater irradiation energy induces cell death by necrosis. (2) When 10-20 microM conjugate and less irradiation energy are used, both necrosis and apoptosis are observed. (3) Using 10 microM and the least irradiation energy, a significant reduction in cell migration is observed, which indicates a reduction in aggressiveness of the cancer cells.
由于糖类在细胞识别、代谢和细胞标记中的作用已得到充分证实,糖类与药物的缀合是一个活跃的研究领域。因此,使用糖类 - 药物缀合物的一个目标是赋予对特定细胞类型或其他靶点更高的特异性。尽管光动力疗法(PDT)中使用的药物广泛用于治疗某些癌症和年龄相关性黄斑变性,但这些药物对预期靶点的化学选择性较差,细胞摄取很可能源于被动扩散过程。相反,靶组织的特异性照射以及原位有毒物种的形成是调节当前PDT模式选择性的主要因素。我们在此报告一种两步法,使用四(五氟苯基)卟啉和糖的硫代衍生物以高产率制备不可水解的糖类 - 卟啉缀合物。作为其性质的证明,研究了这些化合物对几种癌细胞类型的选择性摄取(和/或结合),随后研究了它们的光动力性质。正如预期的那样,不同的恶性细胞类型优先摄取一种糖类 - 卟啉缀合物而不是其他缀合物;例如,人乳腺癌细胞(MDA - MB - 231)吸收四葡萄糖 - 卟啉缀合物而不是相应的半乳糖衍生物。剂量测定研究表明,这些糖类 - 卟啉缀合物根据药物浓度和照射能量表现出不同的PDT反应。(1)使用20 microM缀合物和更高的照射能量会通过坏死诱导细胞死亡。(2)当使用10 - 20 microM缀合物和较低的照射能量时,会观察到坏死和凋亡。(3)使用10 microM和最低的照射能量时,观察到细胞迁移显著减少,这表明癌细胞的侵袭性降低。